Articles About Biotech Investing

These 5 Indicators Tell Me This Stock Will Double by 2020

0 | By Michael A. Robinson

Jara Herron, the owner of a salon and day spa in Tulsa, Okla., had just given birth to her seventh child about six years ago when she suddenly felt her chest getting tighter.

When she got to the hospital, Herron learned she was having a heart attack. Her organs soon began to fail, so doctors put her into a medical coma.

Because Herron was not a candidate for a heart transplant, her doctors instead turned to the world’s smallest heart pump, one that can be inserted with a noninvasive catheter. That heart pump saved Herron’s life.

And it’s done the same thing for thousands of other patients around the United States.

But that’s far from the only thing this innovative heart pump has done.

It’s also helped hand investors 569% gains.

Its maker is a cutting-edge medtech firm with deep expertise with heart patients.

Those big gains are just a start for this life sciences leader.

In fact, it’s set to double your money in as little as two years

As This “Uncivil War” on Pain Escalates, This Biotech Will Be the Surprise Winner

0 | By WIlliam Patalon III

Here’s a brain-bender for you.

Immunalysis Corp., a unit of diagnostic player Alere Inc. (NYSE: ALR), said last week that its supersensitive new test for detecting the opioid painkiller fentanyl received U.S. Food and Drug Administration (FDA) clearance for use by labs, hospitals, and doctors’ offices.

And this new development tells me – yet again – that the market for marijuana-based pain medicines is well into an uptrend that can’t be stopped.

If that seems like an exercise in A + B = C logic, so be it.

I’m going to show you why my logic is right on target.

And I’m going to show you a turnaround candidate that I believe will be a hefty beneficiary of this paradigm shift in “America’s War on Pain.”

This New Year’s, Get Aboard the Wealth Rocket

1 | By Michael A. Robinson

As we approach Christmas and the end of the year, I’m getting ready for one of my favorite nights.

You see, I love New Year’s Eve.

And not because I look forward to the lavish parties folks like to hold on that final night of the year.

In fact, I don’t party at all.

Instead, my wife and I have established a neat little ritual that lets us say adios to the outgoing year and to welcome in the new one by setting some goals for the one that’s coming in.

We dress up and go out for a late dinner – usually at one of the nice local eateries that we like and support. But before we do, the two of us always sit by the fire and have our most important “family talk” of the year.


Each year, you see, I write an “Annual Report” that details our achievements for that year. These include accomplishments at work and in the civic projects we’re involved with, great investments we’ve made, and projects we’ve completed.

As my wife and I sit by the fire, we review that “report” – and celebrate our accomplishments. And then we establish goals for the New Year – creating an “Investment Action Plan” whose success or failure we’ll review at our “chat” the following New Year’s Eve.

I’m sharing this story for a reason: My wife and I have been doing this for more than a decade now. That’s long enough to see that this “tradition” has had a positive impact on our lives.

And it points to a habit that I believe every investor should develop.

I’m talking about developing an Investment Action Plan.

It can help make you a winner.

In fact, it can help make you rich.

And today I’m going to show you how…

On August 1, the Stock Market Changed Forever – Here’s the One Move I Want You to Make

4 | By Michael A. Robinson

August 1, 2016, will go down in history as a milestone in stock market history.

For the first time ever, high-tech companies were the four most valuable companies in the Standard & Poor’s 500 Index.

And most investors and analysts didn’t even notice.

That may not sound like a big deal – but it’s actually huge. In fact, it marks the beginning of a whole new era of technology investing.

That’s what I and my research team determined after spending the last 88 days trying to figure out what this anomaly means. We’ve assessed the situation, done hours of research, and have now put together a comprehensive guide laying out what this new world means for you – and your money.

We’ve identified four profit “windows” from which I’ll be finding the “Singularity Plays” with the best chance of producing 10x gains.

This comprehensive report is absolutely free. I’m sending it to you as part of your Strategic Tech Investor membership.

The only move you have to make is click here to read our report.

These Shifting Currents Could Move Dollars Your Way

0 | By Michael A. Robinson

Deep inside your body, skin, joints and muscles deliver messages to your spinal cord, which uses that information to control your movements. Further, your ears, eyes, mouth, nose and skin deliver messages to your brain, which allows you to react, think and plan – and then direct your body to carry out your decisions.

biotechThat’s the central nervous system.

And those messages come in the form of electric signals.

For decades, doctors have dreamed of being able to harness those electric signals to treat injuries and disease.

And now, thanks to miniature implantable devices that can alter and control the body’s electric signals, that dream is coming true.

Researchers are calling it “bioelectronic medicine.”

Here’s how it will work.

Take, for example, a child with asthma. With bioelectronics, doctors could wrap tiny devices around nerves in the lungs. Employing those devices, doctors could then alter nervous electric signals in order to ease tension in the lungs.

If everything goes right, no more asthma…

And asthma treatments are just the beginning…

Researchers from the company I want to share with you today are confident bioelectronic medicine can also be used to treat other long-term diseases, including diabetes and arthritis.

And now this company is teaming up with Google parent Alphabet, Inc. (Nasdaq: GOOGL) to forge a brand-new $715 million bioelectronics firm.

Those of you who invested in this company back on March 29, when I first told you about it, have already made more than 11% on your money. That’s nearly double the S&P 500’s return over the same period.

And now this pact with Alphabet puts it in line to continue this strong growth, as it helps you get invested in bioelectronics – a sector that Global Market Insights says is growing at more than 10% a year, 10 times faster than the U.S. economy as a whole.

Take a look…

To continue reading click here.

Start Making Your Comeback With This One “Buy”

2 | By Michael A. Robinson

On Tuesday, I told you we have to start getting “choosier” about the stocks we buy.

And I told you I’d be back soon with our prime choice.

Today I’m keeping that promise.

The roller-coaster market we’ve seen over just the past week – though, really, it’s been with us all year long – brings with it great buying opportunities for tech investors. The earlier rallies that were making some stocks so expensive are largely gone.

One of my main jobs here is to help you make good choices when others are panicking.
So today we’re “putting our best foot forward” by taking a look at a tech leader well off Wall Street’s radar (they think it’s merely a “software” company).

I’m talking about quick triple-digit gains – and it’s on sale…

Are Netflix and Intel Treading Water?

0 | By Michael A. Robinson

Michael is focused on one thing during his latest appearance on CNBC – powerhouse stocks. In specific, Intel Corp. (Nasdaq: INTC) and Netflix Inc. (Nasdaq: NFLX).

Both companies just released their quarterly results, and Michael covers what investors need to pay attention to and what the future holds for these two major U.S. tech companies.

To find out which company is treading water and which is on track to become a preeminent global brand, just check out the video.

The Biotech Market Is on Fire

3 | By Michael A. Robinson

Spending on drugs here in the United States increased 13% last year to $374 billion – the single-biggest one-year jump in history. That’s a record-setting 4.3 billion prescriptions filled.

That means spending on drugs is rising at a rate that’s five times faster than the growth of the overall economy.

In other words, despite all the “noise” about biotech being “overheated,” the sector remains full of terrific investment opportunities.

Today, I’m talking with Money Map Press Executive Editor William Patalon III about biotech investing – including specific investments you should be making.

It’s Time to Change the Way You Look at Disney Forever

1 | By Michael A. Robinson

Fitbit Inc. (NYSE: FIT) had a very successful initial public offering (IPO) last week.

Shares of the wearable tech leader soared 48% from their offering price. The success underscores the growth ahead for wearables – especially the health and fitness applications where Fitbit excels.

Forecasters at IDTechEx project sales of wearable electronics will hit $20 billion next year and will be valued at almost $70 billion a decade later.

As much as I like Fitbit and its technology, my concern here is that you could get hurt by chasing this stock. Indeed, the first six months for any IPO is a volatile period in which new issues often give up much of their early gains.

That’s why I think tech investors would do well to take a look at Walt Disney Co. (NYSE: DIS).

You know it as an entertainment powerhouse.

But you need to start looking at the “Mouse House” differently.

Here’s why…

The Best Play in the Hottest Biotech Market on Earth

1 | By Michael A. Robinson

Biotechnology is a big opportunity. And China is a big market.

Combine the two and you have a big potential for investment profits.

In today’s Strategic Tech Investor,I’m talking with Money Map PressExecutive Editor William Patalon III, who also heads up the Private Briefing service, about a big profit play in the Chinese biotech market.

It’s a brand-new recommendation…